Biogen’s Skyclarys Approved In Europe For Friedreich’s Ataxia Treatment
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Biogen Inc. (BIIB) said that the European Commission has authorized Skyclarys (omaveloxolone) for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1231812247-746910dd43274e45bbdc878a0281634c.jpg "Overall Tax Burden by State")
:max_bytes(150000):strip_icc():format(jpeg)/Primary-Image-penfed-cd-rates-may-2023-7497239-73419b3285fd4ce0bb5a632481139517.jpg "Everything You Need to Know About Trust Funds in Canada")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1248470681-c0e2ef0823b7431bb03ee636d9e69937.jpg "Financial Regulators: Who They Are and What They Do")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1347125179-7a42b337d7b04c64af688c51c5ecc66e-cb62760dd37042b38b2405732c898e6b.jpg "What Is the Debt-to-Income Ratio You Need for a Home Equity Loan?")
:max_bytes(150000):strip_icc():format(jpeg)/how-to-build-generational-wealth-2d9bb5344df84574bfd1d81deaa0e848.jpg "How To Build Generational Wealth")